Trials / Completed
CompletedNCT00327249
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- AmpliMed Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imexon |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-07-01
- Completion
- 2008-01-01
- First posted
- 2006-05-18
- Last updated
- 2009-08-11
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00327249. Inclusion in this directory is not an endorsement.